Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Study Summary

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

Conditions

Ovarian Cancer Endometrial Cancer Germ Cell Tumor Testicular Germ Cell Tumor Ovarian Germ Cell Tumor

Interventions / Drugs

XmAb541

View on ClinicalTrials.gov ↗

Sponsor

XNCR

Xencor Inc

Bispecific Antibodies

D38/100

Study Details

Enrollment282 participants

Primary Completion—

Lead SponsorXencor, Inc.

Data Retrieved2026-04-11 04:31:58.925818+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.